ENDPOINTS

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

6 months ago

News Briefing

Novo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C

6 months ago

News Briefing

I-Mab stops work on CD73; Citius to pursue ‘strategic’ options

6 months ago

News Briefing

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

6 months ago

Pharma

FDA+

Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drug

6 months ago

News Briefing

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

6 months ago

News Briefing

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

6 months ago

Deals

News Briefing

Gilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug

6 months ago

News Briefing

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

6 months ago

Special

Pharma

Tessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger

6 months ago

News Briefing

Affimed’s early lung cancer data disappoint; Indapta's $22M round

6 months ago

News Briefing

Candid inks three T cell engager deals; PepGen trial put on hold

6 months ago

News Briefing

Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M milestone

6 months ago

News Briefing

Elevation to pay up to $368M in ADC deal; Bavarian Nordic closes San Diego site

7 months ago

News Briefing

BenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal

7 months ago

News Briefing

CervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drug

7 months ago

News Briefing

Enanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of staff

7 months ago

News Briefing

Teva to divest business venture in Japan; Layoffs at Rome Therapeutics

7 months ago

News Briefing

UK to limit access to Lilly’s Zepbound; VivaVision’s positive Phase 2

7 months ago

News Briefing

AstraZeneca's new EVP of international amid China investigation; Janux’s $300M offering

7 months ago

News Briefing

BMS inks deal with AI Proteins; Terns’ early-stage leukemia data

7 months ago

News Briefing

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

7 months ago

News Briefing

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

7 months ago

News Briefing

Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor

7 months ago

News Briefing

about the author

author articles

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Novo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C

I-Mab stops work on CD73; Citius to pursue ‘strategic’ options

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Hutchmed’s divestiture; Xgene reports Phase 2b win for non-opioid pain drug

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

Gilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Tessera gets up to $50M from the Gates Foundation; Tvardi’s reverse merger

Affimed’s early lung cancer data disappoint; Indapta's $22M round

Candid inks three T cell engager deals; PepGen trial put on hold

Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M milestone

Elevation to pay up to $368M in ADC deal; Bavarian Nordic closes San Diego site

BenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal

CervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drug

Enanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of staff

Teva to divest business venture in Japan; Layoffs at Rome Therapeutics

UK to limit access to Lilly’s Zepbound; VivaVision’s positive Phase 2

AstraZeneca's new EVP of international amid China investigation; Janux’s $300M offering

BMS inks deal with AI Proteins; Terns’ early-stage leukemia data

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor